IDT Corp 8-K Summary: January 4, 2017
Business Context and Reporting Period
This Form 8-K was filed by IDT Corporation on January 10, 2017, reporting an event that occurred on January 4, 2017. The filing addresses a compensatory arrangement approved by the Compensation Committee involving the Chairman of the Board.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a transaction value of $1 million related to the sale of corporate interests.
Material Changes
The material change reported is the approval of a compensatory arrangement with Howard S. Jonas, Chairman of the Board. IDT Corporation agreed to sell 10% of its direct and indirect interest in Cornerstone Pharmaceuticals, Inc. to Mr. Jonas for $1 million. This interest includes a convertible promissory note, a warrant, and certain contractual rights. The purchase price matches the amount IDT originally paid for these interests.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are detailed beyond the description of the transaction. Cornerstone Pharmaceuticals is described as a clinical-stage, oncology-focused company targeting cancer metabolism.
Investor Verification Checklist
- Verify the total value of IDT's remaining interest in Cornerstone Pharmaceuticals, Inc. following the sale of 10%.
- Confirm the specific terms of the convertible promissory note and warrant included in the transferred interest.
- Review the original acquisition cost basis of IDT's stake in Cornerstone Pharmaceuticals to validate the $1 million sale price.
- Check for any related party transaction disclosures in subsequent filings regarding this arrangement.